Skip to main content
  • Home
  •  Silvio Inzucchi

Silvio Inzucchi

Professor of Medicine

Section of Endocrinology, Yale University School of Medicine, New Haven, CT, US

Biography

Dr Silvio Inzucchi is a Professor of Medicine at the Yale University School of Medicine in New Haven, where he serves as Clinical Chief of the Section of Endocrinology, Medical Director of the Yale Diabetes Center, and Program Director of the Endocrinology & Metabolism Fellowship.

Dr Inzucchi has been an invited lecturer both nationally and internationally on many topics, most pertaining to clinical diabetes management. He has authored or co-authored more than 500 manuscripts, chapters, monographs, and abstracts, some published in the most prestigious medical journals, including the New England Journal of Medicine and JAMA.

Featured Courses

Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more
Incretin Management in Type 2 Diabetes
  • 1.00 EBAC

Learning objectives

  • Recall the components of the ‘ominous octet’ & how they contribute to T2DM development
  • Identify underlying facets of clinical inertia in T2DM care
  • Describe how early adoption of intensive glycaemic control leads to better outcomes in T2DM
  • Recall efficacy & the mode of action of various incretin-based treatments
  • Adopt an early, intensive glucose-lowering strategy in appropriate individuals 
  • Select appropriate incretin treatment & dosing regimens according to patient profiles 
  • Identify individuals likely to gain cardiovascular benefit from GLP-1RAs 
  • Select appropriate actions following adverse events from incretin-based treatments
See more